连续B细胞清除利妥昔单抗对ANCA相关血管炎致病自身抗体及总IgG水平的影响
该回顾性分析纳入239例接受利妥昔单抗诱导连续B细胞清除的ANCA相关血管炎患者,评估诱导组(n=52)和维持组(n=237)的ANCA滴度与总IgG变化。诱导期ANCA月降47%-48%,IgG月降6%;维持期(中位2.4年)IgG年降0.6%,新发低丙种球蛋白血症(IgG<400 mg/dl)占4.6%,严重感染率0.85/10患者年且与IgG<400 mg/dl独立相关。
要点
- 诱导期ANCA滴度下降速度远快于总IgG,体现优先清除致病抗体。
- 维持期长期B细胞清除下IgG水平基本稳定,严重感染罕见。
- IgG<400 mg/dl与维持期严重感染独立相关,需关注基线低IgG四分位患者。
核心结论
- B细胞靶向治疗使ANCA滴度相对总IgG优先下降。
- 尽管长期利妥昔单抗维持治疗,IgG水平基本保持稳定,严重感染罕见。
研究设计与样本
- 回顾性分析239例接受利妥昔单抗诱导连续B细胞清除的ANCA相关血管炎患者。
- 分析两个治疗队列:诱导组(n=52)和维持组(n=237)。
- 采用混合效应模型评估ANCA滴度和总Ig水平随时间变化,采用Poisson回归评估维持期严重感染风险因素。
主要发现
- 诱导期IgG水平平均每月下降6%(95%CI 4,8%)。
- 诱导期抗MPO抗体和抗PR3抗体患者ANCA水平分别平均每月下降47%(95%CI 42,52%)和48%(95%CI 42,54%)。
- 维持治疗中位持续时间2.4年(四分位距1.5,4.0年),IgG水平平均每年下降0.6%(95%CI -0.2,1.4%)。
- 维持期新发显著低丙种球蛋白血症(IgG<400 mg/dl)发生率为4.6%,均位于基线IgG最低四分位。
- 维持期严重感染发生率为0.85/10患者年(95%CI 0.66,1.1),与IgG<400 mg/dl独立相关。
关键数值与推荐
- 诱导期IgG月降6%(95%CI 4,8%),抗MPO抗体ANCA月降47%(95%CI 42,52%),抗PR3抗体ANCA月降48%(95%CI 42,54%)。
- 维持期中位2.4年(IQR 1.5,4.0年),IgG年降0.6%(95%CI -0.2,1.4%)。
- 新发显著低丙种球蛋白血症定义为IgG<400 mg/dl,维持期发生率4.6%。
- 严重感染率0.85/10患者年(95%CI 0.66,1.1),独立关联IgG<400 mg/dl。
临床怎么用
- 长期利妥昔单抗维持治疗中应监测IgG水平,尤其基线IgG处于最低四分位者。
- IgG<400 mg/dl提示严重感染风险升高,需加强感染监测与预防。
- ANCA滴度下降快于总IgG,提示B细胞清除对致病抗体有优先抑制效应。
局限性
- 回顾性分析设计,可能存在选择偏倚和信息偏倚。
- 诱导组和维持组样本量不均衡(52例 vs 237例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effect of rituximab on pathogenic autoantibodies and total Ig levels, and to identify serious adverse events in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated with continuous B cell depletion. METHODS: We conducted a retrospective analysis of 239 patients with AAV treated with rituximab-induced continuous B cell depletion. Two treatment cohorts were analyzed: an induction group (n = 52) and a maintenance group (n = 237). Changes in ANCA titers and total Ig levels over time were evaluated using mixed-effects models. Risk factors for serious infections during maintenance treatment were evaluated using Poisson regression. RESULTS: During induction, IgG levels fell at a mean rate of 6% per month (95% confidence interval [95% CI] 4, 8%), while ANCA levels declined at a mean rate of 47% per month (95% CI 42, 52%) and 48% per month (95% CI 42, 54%) for patients with antimyeloperoxidase (anti-MPO) antibodies and those with anti-proteinase 3 (anti-PR3) antibodies, respectively. During maintenance treatment, with a median duration of 2.4 years (interquartile range 1.5, 4.0 years), IgG levels declined a mean of 0.6% per year (95% CI -0.2, 1.4%). New significant hypogammaglobulinemia (IgG level of <400 mg/dl) during maintenance treatment occurred in 4.6% of the patients, all of whom were in the lowest baseline IgG quartile. Serious infections during maintenance therapy occurred at a rate of 0.85 per 10 patient-years (95% CI 0.66, 1.1) and were independently associated with an IgG level of <400 mg/dl. CONCLUSION: B cell-targeted therapy causes a preferential decline in ANCA titers relative to total IgG levels. Despite prolonged maintenance therapy with rituximab, IgG levels remain essentially constant. Serious infections were rare.
引用
- Cortazar FB, Pendergraft WF, Wenger J, et al. Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2017. PMID: 28029751. doi:10.1002/art.40032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。